Okay, let's tackle this question about Plazomicin. The user mentioned it was approved by the FDA recently. First, I need to recall what Plazomicin is. I remember that it's an aminoglycoside antibiotic. Aminoglycosides are used for Gram-negative bacteria, right? So maybe it's for a specific type of infection.

The question is asking about its approved use. I should think about when new antibiotics get approved. Recent approvals might be for resistant strains. Plazomicin is similar to gentamicin but modified to resist some resistance mechanisms. Oh, right, there's a resistance enzyme called aminoglycoside-modifying enzymes (AMEs) that inactivate gentamicin. Plazomicin's structure makes it less susceptible to these enzymes.

So the likely approved use would be for infections caused by multidrug-resistant (MDR) Gram-negative bacteria. Specifically, maybe complicated urinary tract infections (cUTIs) caused by organisms like E. coli that are resistant to other aminoglycosides. I think the FDA approved it for cUTIs in patients with limited treatment options. Let me check if that's correct. Yes, Plazomicin was approved in 2018 for cUTIs, especially when caused by MDR pathogens. So the correct answer would be the option stating that.

Now, looking at the options (though they're not listed here), the other options might include things like MRSA, which is a Gram-positive infection, so aminoglycosides wouldn't be effective. Or maybe for a different type of infection like pneumonia, but aminoglycosides are not first-line for respiratory infections. Alternatively, it might be confused with another antibiotic like ceftaroline, which is for MRSA. So the incorrect options would be related to other bacteria or conditions.

The clinical pearl here is that Plazomicin is a next-generation aminoglycoside designed to overcome resistance, specifically for MDR Gram-negative bacteria in cUTIs. Students should remember that aminoglycosides are not typically used for other infections like skin infections or MRSA, which are Gram-positive. Also, the key point is the modification to avoid AME inactivation.

**Core Concept**
Plazomicin is a next-generation aminoglycoside antibiotic designed to overcome resistance mechanisms in multidrug-resistant (MDR) Gram-negative pathogens. Its approval reflects targeted use in infections where traditional aminoglycosides like gentamicin are ineffective due to enzymatic resistance.

**Why the Correct Answer is Right**
Plazomicin was FDA-approved in 2018 for **complicated urinary tract infections (cUTIs)**, including pyelonephritis, caused by susceptible isolates of *Escherichia coli*, *Klebsiella pneumoniae*, or *Proteus mirabilis*. Its modified structure (2''-N-methyl substitution) prevents inactivation by aminoglycoside-modifying enzymes (AMEs), a major resistance mechanism in MDR Gram-negative bacteria. This makes it effective in infections where gentamicin and other first-line aminoglycosides fail.

**Why Each Wrong Option is Incorrect**
**Option A:** (e.g., "MRSA infections")—Incorrect. MRSA is a Gram-positive path

✓ Correct Answer: B. UTI